Characterizing in vivo pharmacodynamics of carbapenems against acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 599-601

  MacVane, Shawn H ^a   Crandon, Jared L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; CYCLOPHOSPHAMIDE; DORIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LEG DISEASE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THIGH;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; MICE; MICROBIAL SENSITIVITY TESTS; THIGH;

EID: 84891543454     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02029-13     Document Type: Article

References (13)

1. Maragakis LL, Perl TM. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46: 1254-1263. http://dx.doi.org/10.1086/529198.
2. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
3. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052. http://dx.doi.org/10.2165/00003495-200767070-00006.
4. Craig WA, Ebert S, Watanabe Y. 1993. Differences in time above the MIC (T-MIC) required for efficacy of beta-lactams in animal infection models, abstr 86. Prog. Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
5. Drusano GL. 2003. Prevention of resistance: A goal for dose selection of antimicrobial agents. Clin. Infect. Dis. 36(Suppl 1):S42-S50. http://dx.doi.org/10.1086/344653.
6. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal activities of meropenem and ertapenem against extended-spectrum-β- lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481- 1486. http://dx.doi.org/10.1128/AAC.00752-06.
7. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. 2007. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn. Microbiol. Infect. Dis. 57:153-161. http://dx.doi.org/10.1016/j.diagmicrobio.2006.06.014.
8. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin. Infect. Dis. 51:79-84. http://dx.doi.org/10.1086/653120.
9. Clinical and Laboratory Standards Institute. 2013. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; approved standard-. 9th ed. CLSI publication M07-A9. Clinical Laboratory Standards Institute, Wayne, PA.
10. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam- avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-β-lactamase producers. Antimicrob. Agents Chemother. 57:3299-3306. http://dx.doi.org/10.1128/AAC.01989-12.
11. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin- clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
12. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502. http://dx.doi.org/10.1128/AAC.01252- 07.
13. Craig WA. 1998. Pharmacokinetics and pharmacodynamics of antibiotics in mice and men. Clin. Infect. Dis. 26:1-12. http://dx.doi.org/10.1086/516284.